Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$376.60 USD

376.60
385,762

-4.26 (-1.12%)

Updated Aug 6, 2025 12:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Indrajit Bandyopadhyay headshot

What's in Store for These 5 Medical Device Stocks in Q1 Earnings?

by Indrajit Bandyopadhyay

Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.

Zacks Equity Research

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Seeking Clues to Stryker (SYK) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Stryker (SYK) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Urmimala Biswas headshot

SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?

by Urmimala Biswas

SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.

Zacks Equity Research

Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings

by Zacks Equity Research

Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Zacks Equity Research

Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay

by Zacks Equity Research

Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

Zacks Equity Research

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

by Zacks Equity Research

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Zacks Equity Research

Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.

Zacks Equity Research

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).

Zacks Equity Research

Smith+Nephew (SNN) Expands in Australia With New Alliance

by Zacks Equity Research

The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.

Zacks Equity Research

Align Technology (ALGN) Up 20.5% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.

Zacks Equity Research

Boston Scientific (BSX) Faces Rising Costs, Competition

by Zacks Equity Research

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.

Zacks Equity Research

Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes

by Zacks Equity Research

Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.

Zacks Equity Research

Bruker (BRKR) Introduces Magnet Technology for NMR Adoption

by Zacks Equity Research

Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.

Zacks Equity Research

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.

Zacks Equity Research

Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers

by Zacks Equity Research

Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.

Zacks Equity Research

Abbott (ABT) Faces Low Testing Demand, Currency Headwinds

by Zacks Equity Research

Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.

Zacks Equity Research

IM Cannabis (IMCC) Expands Business in Germany With New Alliance

by Zacks Equity Research

The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.

Zacks Equity Research

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.

Zacks Equity Research

Labcorp (LH) Extends MRD Clinical Research With New Launch

by Zacks Equity Research

Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.

Zacks Equity Research

Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC

by Zacks Equity Research

Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.